Cizzle Bio Announces Laboratory Validation of CIZ1B Biomarker Blood Test for Early Lung Cancer at OmniHealth Diagnostics
Summary
Cizzle Bio completed laboratory validation of its CIZ1B biomarker blood test for early lung cancer at OmniHealth Diagnostics. The company is now finishing launch readiness work and expects the test to become available to U.S. healthcare providers soon. The assay uses a small blood sample and is designed to complement low-dose CT screening by improving risk stratification and reducing diagnostic uncertainty. Cizzle Bio plans to expand validation with additional CLIA-certified laboratory partners as it broadens access to the test.
Classifications
industries
HealthTech
applications
Governance, risk and compliance
AskAI Classifications
Labels
No AI classifications detected